Sydney most cancers medtech startup Lumonus, has added a further $3 million to its Sequence B, 4 months on, to take the overall raised to $28 million.
Brandon Capital and Investible joined the spherical, led by Aviron Funding Administration with assist from current investor Oncology Ventures, which backed a Seed spherical in March 2025. The preliminary $25m Series B raise was announced last November.
The scientific care platform, based in 2024, makes use of AI for radiation oncology workflow automation and is used within the US, Australia and Europe. Clinicians have used it seek the advice of and prescribe on greater than 280,000 most cancers therapies, automating greater than 75,000r therapy plans.
The funds will likely be used to broaden the US go-to-market and scientific success groups, scientific informatics capabilities, and enhance its flagship merchandise, Lumonus AI Doctor and Lumonus AI Dosimetry, for extra personalised, data-driven care.
Lumonus CEO Keith Hansen mentioned oncology (most cancers prognosis and therapy) is at an inflection level
“Scientific innovation in most cancers therapy has superior considerably, however the methods that assist groups delivering the care haven’t stored tempo,” he mentioned
“By combining AI-native structure, a complete end-to-end workflow method, and a dedication to partnering with care groups to unravel real-world ache factors, we’re reimagining oncology workflows. This funding permits us to broaden our world-class workforce and assist extra well being methods which are able to embrace a greater manner.”
